BRAF and melanoma: The phase I/II clinical trial KEYNOTE-022 enrolled 120 subjects with unresectable locally advanced or metastatic BRAF V600E- or V600K-mutant melanoma who were randomly assigned to be treated with dabrafenib 150 mg BID and trametinib 2 mg daily combined with pembrolizumab 200 mg 3-weekly or placebo [13].